Login to Your Account

Other News To Note

Tuesday, December 3, 2013
• Baxter International Inc., of Deerfield, Ill., and Halozyme Therapeutics Inc. jointly reported that Baxter has completed submission of an amended biologics license application (BLA) to the FDA to re-initiate the review process for approval of Hyqvia [immune globulin infusion 10% (human) with recombinant human hyaluronidase] facilitated subcutaneous infusion for the treatment of adult patients with primary immunodeficiency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription